AI assistant
Abnova — Investor Presentation 2020
Sep 22, 2020
52384_rns_2020-09-22_c0608b75-7a3d-467a-9ab8-83bfd039296a.pdf
Investor Presentation
Open in viewerOpens in your device viewer
==> picture [794 x 119] intentionally omitted <==
==> picture [794 x 359] intentionally omitted <==
1
免責聲明
本簡報及同時發佈之相關訊息包含財務、市場暨產品業務等預測性 資訊。本公司未來實際發生的營運結果及財務狀況可能與這些預測性資 訊所明示或暗示的預估有所差異,其原因可能來自於各種本公司所不能 掌控的風險。這些預估及展望的訊息,反應本公司截至目前為止對於未 來的看法,本公司並不負責隨時提醒或更新。
2
議程
✓ 公司簡介
- 2020年第二季&上半年財務成果
✓ 亞諾法COVID‐19產品說明
✓ Q&A
==> picture [794 x 120] intentionally omitted <==
3
==> picture [794 x 119] intentionally omitted <==
==> picture [794 x 121] intentionally omitted <==
==> picture [794 x 120] intentionally omitted <==
I. 亞諾法公司簡介
4
亞諾法公司簡介
==> picture [794 x 359] intentionally omitted <==
5
2020年第二季及上半年合併損益表
In NT$K
| Q2‘20 | % | Q2‘19 | % | H1‘20 | % | H1‘19 | % | H1 YOY | |
|---|---|---|---|---|---|---|---|---|---|
| 營業收入 | 103,319 | 100% | 103,591 | 100.00% | 203,229 | 100.00% | 212,172 | 100.00% | (4.21%) |
| 營業成本 | (56,609) | (54.79%) | (59,721) | (57.7%) | (110,523) | (54.38%) | (125,624) | (59.2%) | (12.02%) |
| 營業毛利 | 46,710 | 45.21% | 43,870 | 42.3% | 92,706 | 45.62% | 86,548 | 40.8% | 7.12% |
| 營業費用 | (38,309) | (37.08%) | (45,306) | (43.7%) | (77,020) | (38.90%) | (90,616) | (42.7%) | (15.00%) |
| 營業利益 | 8,401 | 8.13% | (1,436) | (1.4%) | 15,686 | 6.72% | (4,068) | (1.9%) | 485.59% |
| 營業外收入及支出 | (3,009) | (2.91%) | 2,374 | 2.3% | (900) | (1.44%) | 3,133 | 1.5% | (128.73%) |
| 稅前淨利 | 5,392 | 5.22% | 938 | 0.9% | 14,786 | 6.28% | (935) | (0.4%) | 1681.39% |
| 稅後淨利 | 4,122 | 3.99% | 2,503 | 2.4% | 11,818 | 4.82% | 634 | 0.3% | 1764.04% |
| 基本每股盈餘 | 0.07 | 0.04 | 0.2 | 0.01 |
6
產品別營收分析
==> picture [794 x 359] intentionally omitted <==
----- Start of picture text -----
In NT$K
2020 Jan-Aug
450,000
400,000
101,562
350,000
300,000 21%
64,473
61,959
250,000
Antibody
49,215
200,000 50% Protein
36,224 Others
150,000
17%
248,123 COVID-19 related
100,000
146,651
50,000
12%
0
2019 2020 Jan-Aug
----- End of picture text -----
抗體 蛋白質 其他 COVID-19 相關
7
==> picture [794 x 119] intentionally omitted <==
==> picture [794 x 359] intentionally omitted <==
8
==> picture [794 x 119] intentionally omitted <==
==> picture [794 x 121] intentionally omitted <==
==> picture [794 x 120] intentionally omitted <==
II. 亞諾法 COVID‐19 產品
9
COVID‐19 自動化RNA 萃取系統
==> picture [794 x 121] intentionally omitted <==
==> picture [794 x 120] intentionally omitted <==
==> picture [670 x 170] intentionally omitted <==
10
抗體快速檢測試劑 COVID‐19 IgM IgG
-
快速, 便利, 可靠
-
• 15 分鐘即可獲得結果
-
操作簡易
-
結果可直接清楚辨識
指尖血檢測
==> picture [276 x 124] intentionally omitted <==
CE IVD Approved
==> picture [794 x 120] intentionally omitted <==
11
酵素免疫分析試劑組 COVID‐19 IgM IgG
COVID-19 IgM IgG 酵素免疫分析試劑組係利用檢測血清中IgM及IgG抗體 之定性檢測
12
COVID‐19 抗原快速檢測試劑 (Pending)
==> picture [598 x 307] intentionally omitted <==
13
COVID‐19 病毒抗原酵素免疫分析試劑組
Sandwich enzyme‐linked immunosorbent assays for the quantitative measurement of COVID‐19 viral or . spike antigen nucleocapsid antigen
COVID‐19 Viral Antigen S ELISA Kit COVID‐19 Viral Antigen N ELISA Kit (S棘醣蛋白) (N核蛋白)
==> picture [794 x 120] intentionally omitted <==
14
COVID‐19 中和性抗體檢測
==> picture [794 x 415] intentionally omitted <==
----- Start of picture text -----
Serum Pseudovirus
Spike protein
Pseudovirus infected and cells
expressed luciferase
Neutralized
----- End of picture text -----
==> picture [174 x 18] intentionally omitted <==
----- Start of picture text -----
Pseudovirus/Antibody
----- End of picture text -----
==> picture [95 x 12] intentionally omitted <==
----- Start of picture text -----
293T‐ACE2 cell
----- End of picture text -----
Without luciferase expression
15
COVID‐19 治療性抗體
(A) Antibody with Spike protein
==> picture [102 x 179] intentionally omitted <==
==> picture [105 x 120] intentionally omitted <==
----- Start of picture text -----
Antibody
Spike protein
----- End of picture text -----
(B) Antibody with Pseudovirus
==> picture [295 x 179] intentionally omitted <==
==> picture [385 x 225] intentionally omitted <==
----- Start of picture text -----
Flow cytometer analysis
Neutralized Non‐neutralized
Mouse IgG
----- End of picture text -----
==> picture [397 x 199] intentionally omitted <==
----- Start of picture text -----
Luciferase activity assay
----- End of picture text -----
3株候選抗體已有1株完成人類化
16
技術開發COVID-19疫苗 Self‐Amplifying mRNA (Pending)
==> picture [699 x 297] intentionally omitted <==
==> picture [699 x 149] intentionally omitted <==
17
==> picture [794 x 119] intentionally omitted <==
==> picture [794 x 121] intentionally omitted <==
==> picture [794 x 120] intentionally omitted <==
==> picture [794 x 120] intentionally omitted <==
18